Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review

Brandon Stretton; Joshua Kovoor; Stephen Bacchi; Shantel Chang; Benjamin Ngoi; Tess Murray; Thomas C. Bristow; Jonathan Heng; Aashray Gupta; Christopher Ovenden; Guy Maddern; Campbell H. Thompson; Leonie Heilbronn; Mark Boyd; Christopher Rayner; Nicholas J. Talley; Michael Horowtiz

doi:10.1111/imj.16126

Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review

Brandon Stretton, Joshua Kovoor, Stephen Bacchi, Shantel Chang, Benjamin Ngoi, Tess Murray, Thomas C. Bristow, Jonathan Heng, Aashray Gupta, Christopher Ovenden, Guy Maddern, Campbell H. Thompson, Leonie Heilbronn, Mark Boyd, Christopher Rayner, Nicholas J. Talley, Michael Horowtiz

Obesity & Metabolism

Research output: Contribution to journal › Review article › peer-review

16 Citations (Scopus)

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce elevated blood glucose levels and induce weight loss. Multiple GLP-1 RAs and one combined GLP-1/glucose-dependent insulinotropic polypeptide agonist are currently available. This review was conducted with the aim of summarising direct comparisons between subcutaneous semaglutide and other GLP-1 RAs in individuals with type 2 diabetes (T2D), particularly with respect to efficacy for inducing weight loss and improving other markers of metabolic health. This systematic review of PubMed and Embase from inception to early 2022 was registered on PROSPERO and was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-Analysis of Observational Studies in Epidemiology guidelines. Of the 740 records identified in the search, five studies fulfilled the inclusion criteria. Comparators included liraglutide, exenatide, dulaglutide and tirzepatide. In the identified studies, multiple dosing regimens were utilised for semaglutide. Randomised trials support the superior efficacy of semaglutide over other GLP-1 RAs with respect to weight loss in T2D, but tirzepatide is more effective than semaglutide.

Original language	English
Pages (from-to)	1311-1320
Number of pages	10
Journal	Internal Medicine Journal
Volume	53
Issue number	8
DOIs	https://doi.org/10.1111/imj.16126
Publication status	Published or Issued - Aug 2023

Keywords

obesity
type 2 diabetes
weight loss

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1111/imj.16126

Cite this

Stretton, B., Kovoor, J., Bacchi, S., Chang, S., Ngoi, B., Murray, T., Bristow, T. C., Heng, J., Gupta, A., Ovenden, C., Maddern, G., Thompson, C. H., Heilbronn, L., Boyd, M., Rayner, C., Talley, N. J., & Horowtiz, M. (2023). Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review. Internal Medicine Journal, 53(8), 1311-1320. https://doi.org/10.1111/imj.16126

@article{a4d3c1ad0e594026bfdae645c131cbb5,

title = "Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review",

abstract = "Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce elevated blood glucose levels and induce weight loss. Multiple GLP-1 RAs and one combined GLP-1/glucose-dependent insulinotropic polypeptide agonist are currently available. This review was conducted with the aim of summarising direct comparisons between subcutaneous semaglutide and other GLP-1 RAs in individuals with type 2 diabetes (T2D), particularly with respect to efficacy for inducing weight loss and improving other markers of metabolic health. This systematic review of PubMed and Embase from inception to early 2022 was registered on PROSPERO and was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-Analysis of Observational Studies in Epidemiology guidelines. Of the 740 records identified in the search, five studies fulfilled the inclusion criteria. Comparators included liraglutide, exenatide, dulaglutide and tirzepatide. In the identified studies, multiple dosing regimens were utilised for semaglutide. Randomised trials support the superior efficacy of semaglutide over other GLP-1 RAs with respect to weight loss in T2D, but tirzepatide is more effective than semaglutide.",

keywords = "obesity, type 2 diabetes, weight loss",

author = "Brandon Stretton and Joshua Kovoor and Stephen Bacchi and Shantel Chang and Benjamin Ngoi and Tess Murray and Bristow, {Thomas C.} and Jonathan Heng and Aashray Gupta and Christopher Ovenden and Guy Maddern and Thompson, {Campbell H.} and Leonie Heilbronn and Mark Boyd and Christopher Rayner and Talley, {Nicholas J.} and Michael Horowtiz",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.",

year = "2023",

month = aug,

doi = "10.1111/imj.16126",

language = "English",

volume = "53",

pages = "1311--1320",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

Stretton, B, Kovoor, J, Bacchi, S, Chang, S, Ngoi, B, Murray, T, Bristow, TC, Heng, J, Gupta, A, Ovenden, C, Maddern, G, Thompson, CH, Heilbronn, L, Boyd, M, Rayner, C, Talley, NJ & Horowtiz, M 2023, 'Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review', Internal Medicine Journal, vol. 53, no. 8, pp. 1311-1320. https://doi.org/10.1111/imj.16126

TY - JOUR

T1 - Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes

T2 - a systematic review

AU - Stretton, Brandon

AU - Kovoor, Joshua

AU - Bacchi, Stephen

AU - Chang, Shantel

AU - Ngoi, Benjamin

AU - Murray, Tess

AU - Bristow, Thomas C.

AU - Heng, Jonathan

AU - Gupta, Aashray

AU - Ovenden, Christopher

AU - Maddern, Guy

AU - Thompson, Campbell H.

AU - Heilbronn, Leonie

AU - Boyd, Mark

AU - Rayner, Christopher

AU - Talley, Nicholas J.

AU - Horowtiz, Michael

PY - 2023/8

Y1 - 2023/8

N2 - Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce elevated blood glucose levels and induce weight loss. Multiple GLP-1 RAs and one combined GLP-1/glucose-dependent insulinotropic polypeptide agonist are currently available. This review was conducted with the aim of summarising direct comparisons between subcutaneous semaglutide and other GLP-1 RAs in individuals with type 2 diabetes (T2D), particularly with respect to efficacy for inducing weight loss and improving other markers of metabolic health. This systematic review of PubMed and Embase from inception to early 2022 was registered on PROSPERO and was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-Analysis of Observational Studies in Epidemiology guidelines. Of the 740 records identified in the search, five studies fulfilled the inclusion criteria. Comparators included liraglutide, exenatide, dulaglutide and tirzepatide. In the identified studies, multiple dosing regimens were utilised for semaglutide. Randomised trials support the superior efficacy of semaglutide over other GLP-1 RAs with respect to weight loss in T2D, but tirzepatide is more effective than semaglutide.

AB - Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce elevated blood glucose levels and induce weight loss. Multiple GLP-1 RAs and one combined GLP-1/glucose-dependent insulinotropic polypeptide agonist are currently available. This review was conducted with the aim of summarising direct comparisons between subcutaneous semaglutide and other GLP-1 RAs in individuals with type 2 diabetes (T2D), particularly with respect to efficacy for inducing weight loss and improving other markers of metabolic health. This systematic review of PubMed and Embase from inception to early 2022 was registered on PROSPERO and was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-Analysis of Observational Studies in Epidemiology guidelines. Of the 740 records identified in the search, five studies fulfilled the inclusion criteria. Comparators included liraglutide, exenatide, dulaglutide and tirzepatide. In the identified studies, multiple dosing regimens were utilised for semaglutide. Randomised trials support the superior efficacy of semaglutide over other GLP-1 RAs with respect to weight loss in T2D, but tirzepatide is more effective than semaglutide.

KW - obesity

KW - type 2 diabetes

KW - weight loss

UR - http://www.scopus.com/inward/record.url?scp=85162717995&partnerID=8YFLogxK

U2 - 10.1111/imj.16126

DO - 10.1111/imj.16126

M3 - Review article

C2 - 37189293

AN - SCOPUS:85162717995

SN - 1444-0903

VL - 53

SP - 1311

EP - 1320

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 8

ER -

Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this